Periostin levels and eosinophilic inflammation in poorly-controlled asthma

[1]  R. Maciuca,et al.  Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies , 2015, Thorax.

[2]  R. Lutter,et al.  External validation of blood eosinophils, FENO and serum periostin as surrogates for sputum eosinophils in asthma , 2014, Thorax.

[3]  K. Izuhara,et al.  Association of serum periostin with aspirin-exacerbated respiratory disease. , 2014, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[4]  P. Gibson,et al.  Full blood count parameters for the detection of asthma inflammatory phenotypes , 2014, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[5]  N. Jarjour,et al.  The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge , 2013, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[6]  S. Phipps,et al.  Elevated expression of the NLRP3 inflammasome in neutrophilic asthma , 2013, European Respiratory Journal.

[7]  W. Busse,et al.  Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. , 2013, American journal of respiratory and critical care medicine.

[8]  D. Wishart,et al.  Translational biomarker discovery in clinical metabolomics: an introductory tutorial , 2012, Metabolomics.

[9]  Nicola A Hanania,et al.  Lebrikizumab treatment in adults with asthma. , 2011, The New England journal of medicine.

[10]  S. Mosesova,et al.  Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. , 2011, The Journal of allergy and clinical immunology.

[11]  S. Muller,et al.  Roles of epithelial cell-derived periostin in TGF-β activation, collagen production, and collagen gel elasticity in asthma , 2010, Proceedings of the National Academy of Sciences.

[12]  Barmak Modrek,et al.  T-helper type 2-driven inflammation defines major subphenotypes of asthma. , 2009, American journal of respiratory and critical care medicine.

[13]  I. Pavord,et al.  An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. , 2009, American journal of respiratory and critical care medicine.

[14]  Yee Hwa Yang,et al.  Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids , 2007, Proceedings of the National Academy of Sciences.

[15]  L. Boulet,et al.  Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations , 2006, European Respiratory Journal.

[16]  I. Pavord,et al.  Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial , 2002, The Lancet.

[17]  A. Cripps,et al.  Epidemiological association of airway inflammation with asthma symptoms and airway hyperresponsiveness in childhood. , 1998, American journal of respiratory and critical care medicine.